Abbasi M,Mousavi MJ,Jamalzehi S MJ .2019 .Strategies toward RA therapy. J Cell Physiol, 234(7) : 10018-10031.
Alamanos Y,Drosos AA Y .2005 .Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev., 4(3) : 130-136.
Amaya-Amaya J,Botello-Corzo D,Calixto OJ D .2012 .Usefulness of patient-reported outcomes in rheumatoid arthritis. Arthritis., : 935187.
Anaya JM,Correa PA,Mantilla RD .2001 .Rheumatoid arthritis in African Colombians. , 31(3) : 191-198.
Bass AR,Abdel-Wahab N,Reid PD .2023 .Comparative safety of TNF inhibitors. , 82(7) : 920-926.
Cadena J,Vinaccia S,Pérez A,Rico MI .2003 .The impact of disease activity on quality of life in RA patients. J. Clin. Rheumatol., 9(3) : 142-150.
Coates LC,Helliwell PS .2016 .Psoriatic arthritis: Therapies and outcomes. Arthritis. Res. Ther., 18(1) : 128.
Delgado-Vega AM,Martín J,Granados J .2006 .Genetic epidemiology of RA in Latin America. , 26(4) : 562-584.
DeMaria AN .2002 .Relative risk of cardiovascular events in RA. Am. J. Cardiol., 89(1 Suppl)) : 33D-38D.
Feldmann M and Maini R N .2001 .Role of TNF in RA pathogenesis and therapy. Annu. Rev. Immunol., 19 : 163-196.
Firestein GS .2003 .Evolving concepts of RA pathogenesis. Nature, 423(6937) : 356-361.
Gregori D,Giacovelli G,Minto C .2018 .Association of treatments with pain control in osteoarthritis. J Am Med Assoc., 320(24) : 2564-2579.
Ding Karlson E W,Keenan B,B T B .2013 .Geneenvironment interactions in RA. Arthrit. Care Res., 65(8) : 1147-1156.
Lübbers J,Brink M,Van de Stadt LA,Huizinga TW .2013 .Type I IFN signature as a biomarker. , 72(5) : 776-780.
Lyseng-Williamson KA .2018 .Anakinra in Still's disease: A profile. Drugs Ther, 34(12) : 543-553.
Kolls Miossec P,JK Miossec P .2012 .Targeting IL-17 in RA. Nat. Rev. Drug Discov, 11(10) : 763-776.
Peters MJ,Symmons DP,McCarey D,Kitas GD D .2010 .EULAR recommendations for cardiovascular risk in RA. , 69(2) : 325-331.
Rindfleisch JA,Muller D JA .2005 .Diagnosis and management of RA. Am. Fam. Phys., 72(6) : 1037-1047.
Rojas-Villarraga A,Bayona J,Zuluaga N,Mejía S N .2009 .The impact of rheumatoid foot on disability. BMC Musculoskel. Dis., 10 : 67.
Rose N,Furer V,Polachek A .2024 .Immune checkpoint inhibitor-induced arthritis. Eur. J. Rheumatol., 11(1) : 27-32.
Sandoo A,Carroll D,Metsios GS,Kitas GD,Veldhuijzen van Zanten JJ .2011 .Association between endothelial function in RA. Arthritis. Res. Ther., 13(4) : R99.
Scott DL,Wolfe F,Huizinga TW .2010 .Rheumatoid arthritis. The Lancet. , 376(9746) : 1094-1108.
Smolen JS,Aletaha D,McInnes IB .2016 .RA therapies and clinical outcomes. The Lancet. , 388(10055) : 2023-2038.
Sokka T,Häkkinen A,Krishnan E,Hannonen P .2004 .Similar prediction of mortality by the health assessment questionnaire. , 63(4) : 494-497.
Van den Broek M,Dirven L,De Vries-Bouwstra J K and Allaart CF L .2012 .Radiological progression predictive of disability. , 71(9) : 1530-1533.
Van Riel PL,Fransen J .2007 .Established rheumatoid arthritis: Clinical assessments. Best Pract. Res. Clin. Rheumatol, 21(5) : 807-825.
Wolfe F .2000 .A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis, 43(12) : 2751-2761.